In a recent press release, biopharmaceutical company Ultragenyx Pharmaceutical Inc. (“Ultragenyx”) shared positive safety and efficacy data from Phase 1/2 clinical trials on gene
In a press release from early January 2021, genetic medicines company Generation Bio Co. (“Generation Bio”) announced data from a variety of studies. In
Recently, BiocurePharm, Korea (“BPK”), a subsidiary of biopharmaceutical company Brochure Technology Corp., shared that it had entered into a memorandum of understanding (MOU) with Symbasis
Kohl’s has brought a new clothing line whose target audience is rare disease patients. The new clothing includes adaptive options to allow easy access to
Welcome to study of the week, a new series from Patient Worthy. In this segment, we select a study we posted about from the previous
BPD Bronchopulmonary dysplasia (BPD) is a rare condition that primarily affects the lungs of premature babies (though it can affect full term newborns as well). Most
© Copyright Patient Worthy
